Perspective Therapeutics
CATX
103 hedge funds and large institutions have $296M invested in Perspective Therapeutics in 2024 Q1 according to their latest regulatory filings, with 56 funds opening new positions, 22 increasing their positions, 10 reducing their positions, and 5 closing their positions.
1,752% more capital invested
Capital invested by funds: $16M → $296M (+$280M)
1,020% more first-time investments, than exits
New positions opened: 56 | Existing positions closed: 5
120% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 10
98% more funds holding
Funds holding: 52 → 103 (+51)
3.7% more ownership
Funds ownership: 1.3% → 5.01% (+3.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$24M |
| 2 |
CC
Commodore Capital
New York
|
+$18M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$16.2M |
| 4 |
OCA
Octagon Capital Advisors
New York
|
+$12.6M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$11.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$6.39M |
| 2 |
TMWM
Taylor & Morgan Wealth Management
Flint,
Michigan
|
-$320K |
| 3 |
OCM
Osterweis Capital Management
San Francisco,
California
|
-$288K |
| 4 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
-$281K |
| 5 |
Renaissance Technologies
New York
|
-$234K |
CATX Hedge Fund Activity: Q1 2024 in Review
103 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Perspective Therapeutics (CATX) for Q1 2024, worth a combined $296M — up 1,752% from $16M a quarter earlier.
Buyers outnumbered sellers: 56 funds opened new CATX positions and 5 closed out — a net gain of 51 holders — while 22 added to existing stakes and 10 trimmed.
The largest buyer was Deerfield Management, opening a new position worth an estimated $24M. The largest seller was Baker Bros. Advisors, cutting an estimated $6.39M.
- 103 institutional investors held Perspective Therapeutics (CATX) as of Q1 2024, up from 52 in Q4 2023.
- Funds reported $296M of Perspective Therapeutics stock for Q1 2024, up 1,752% quarter-over-quarter.
- 56 funds opened new Perspective Therapeutics positions in Q1 2024 and 5 closed out, a net change of +51 holders.
- The largest Perspective Therapeutics buyer in Q1 2024 was Deerfield Management, an estimated $24M added.
- The largest Perspective Therapeutics seller in Q1 2024 was Baker Bros. Advisors, an estimated $6.39M sold.
Based on aggregated 13F filings for Q1 2024.